Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Clinical Investigation

  • <sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
    You have access
    68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
    Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T. Siveke, Ken Herrmann, Rainer Hamacher and Wolfgang P. Fendler
    Journal of Nuclear Medicine June 1, 2024, 65 (6) 880-887; DOI: https://doi.org/10.2967/jnumed.123.267248
  • RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    You have access
    RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Andrei Gafita, Loic Djaileb, Isabel Rauscher, Wolfgang P. Fendler, Boris Hadaschik, Steven P. Rowe, Ken Herrmann, Lilja B. Solnes, Jeremie Calais, Matthew B. Rettig, Manuel Weber, Andrea Farolfi, Matthias R. Benz and Matthias Eiber
    Journal of Nuclear Medicine June 1, 2024, 65 (6) 917-922; DOI: https://doi.org/10.2967/jnumed.123.267234
  • You have access
    Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China
    Liang Zhao, Fei Kang, Yizhen Pang, Jianyang Fang, Long Sun, Hua Wu, XiaoLi Lan, Jing Wang and Haojun Chen
    Journal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 4S-11S; DOI: https://doi.org/10.2967/jnumed.123.266983
  • Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with <sup>68</sup>Ga-N188
    You have access
    Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68Ga-N188
    Jianhua Zhang, Xiaojiang Duan, Xueqi Chen, Zhuochen Zhang, Hongwei Sun, Jiayin Shou, Guangyu Zhao, Jianxin Wang, Yongsu Ma, Yinmo Yang, Xiaodong Tian, Qi Shen, Wei Yu, Zhisong He, Yan Fan and Xing Yang
    Journal of Nuclear Medicine May 1, 2024, 65 (Supplement 1) 12S-18S; DOI: https://doi.org/10.2967/jnumed.123.266830
  • High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET
    You have access
    High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET
    Yiran Wang, Yasser G. Abdelhafez, Benjamin A. Spencer, Rashmi Verma, Mamta Parikh, Nicholas Stollenwerk, Lorenzo Nardo, Terry Jones, Ramsey D. Badawi, Simon R. Cherry and Guobao Wang
    Journal of Nuclear Medicine May 1, 2024, 65 (5) 714-721; DOI: https://doi.org/10.2967/jnumed.123.267036
  • <sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
    You have access
    18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
    Samuel L. Cytryn, Neeta Pandit-Taskar, Melissa A. Lumish, Steven B. Maron, Ping Gu, Geoffrey Y. Ku, Joanne F. Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, Lara Feder, Steven Philemond, Serge K. Lyashchenko, Jason S. Lewis, Viktoriya Paroder, Amitabh Srivastava, Laura H. Tang, Heiko Schoder and Yelena Y. Janjigian
    Journal of Nuclear Medicine May 1, 2024, 65 (5) 722-727; DOI: https://doi.org/10.2967/jnumed.123.267186
  • Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
    You have access
    Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
    Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escriva-de-Romani, Lourdes Calvo Martínez, Nuria Ribelles, María Fernandez-Abad, Cinta Albacar, Marco Colleoni, Laia Garrigos, Manuel Atienza de Frutos, Florence Dalenc, Aleix Prat, Frederik Marmé, Peter Schmid, Khaldoun Kerrou, Sofia Braga, Petra Gener, Miguel Sampayo-Cordero, Javier Cortés, José Manuel Pérez-García and Antonio Llombart-Cussac
    Journal of Nuclear Medicine May 1, 2024, 65 (5) 708-713; DOI: https://doi.org/10.2967/jnumed.123.266384
  • Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging
    You have access
    Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging
    Attila Feher, Bryan Bednarski, Robert J. Miller, Aakash Shanbhag, Mark Lemley, Leonidas Miras, Albert J. Sinusas, Edward J. Miller and Piotr J. Slomka
    Journal of Nuclear Medicine May 1, 2024, 65 (5) 768-774; DOI: https://doi.org/10.2967/jnumed.123.266761
  • Cancer Risk in Graves Disease with Radioactive <sup>131</sup>I Treatment: A Nationwide Cohort Study
    You have access
    Cancer Risk in Graves Disease with Radioactive 131I Treatment: A Nationwide Cohort Study
    Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik and Sin Gon Kim
    Journal of Nuclear Medicine May 1, 2024, 65 (5) 693-699; DOI: https://doi.org/10.2967/jnumed.123.266531
  • You have access
    Kick-Starting Molecular Theranostics in Renal Cell Carcinoma
    Viktor Grünwald, Boris Hadschik, Niklas Klümper and Ken Herrmann
    Journal of Nuclear Medicine May 1, 2024, 65 (5) 744-745; DOI: https://doi.org/10.2967/jnumed.124.267618

Pages

  • Previous
  • Next
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 91
SNMMI

© 2025 SNMMI

Powered by HighWire